Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3037% below fair value
$3.69−0.21 (-5.38%)
Close on Nov 18, 2026Market cap $104.15MP/E –Yield –
Journey Medical free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Journey Medical's free cash flow for the twelve months ending Dec 31, 2023 was $240.00K. For fiscal 2024 it was -$24.13M, down 10152.9% from the year before.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$24.13M | -10152.9% |
| FY2023 | Dec 31, 2023 | $240.00K | – |
| FY2022 | Dec 31, 2022 | -$33.53M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$16.52M | – |
| Q3 FY2023 | Sep 30, 2023 | $18.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.84M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.12M | – |
See a number that looks wrong?